ライフサイエンスコーパス: rivaroxaban

1 ed on warfarin or NOAC (either dabigatran or rivaroxaban).

2 g WRF patients randomized to warfarin versus rivaroxaban.

3 lysis patients are started on dabigatrian or rivaroxaban.

4 mbolic events early after discontinuation of rivaroxaban.

5 p = 0.006), which was not seen with 5 mg of rivaroxaban.

6 amilton patients with acute HIT treated with rivaroxaban.

7 1518 to receive aspirin and 1519 to receive rivaroxaban.

8 asing, with the most experience reported for rivaroxaban.

9 oagulation: 0.49% (95% CrI, 0.29%-0.85%) for rivaroxaban, 0.28% (95% CrI, 0.14%-0.50%) for apixaban,

10 ng were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaro

11 nd 5,301 (90%) patients were taking low-dose rivaroxaban (10 to 15 mg once daily) and dabigatran (110

12 hours, 251 were taking NOACs (dabigatran 87, rivaroxaban 129, and apixaban 35) before their stroke, 1

13 K antagonists (VKA) (42%), dabigatran (29%), rivaroxaban (13%), or apixaban (16%) were included with

14 ized 1:1:1 to administration of reduced-dose rivaroxaban 15 mg daily plus a P2Y12 inhibitor for 12 mo

15 acoronary stenting, administration of either rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy

16 =272) receiving uninterrupted periprocedural rivaroxaban 15 or 20 mg/d before the procedure (rivaroxa

17 nting to receive, in a 1:1:1 ratio, low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor fo

18 randomly assigned in a 1:1 ratio to receive rivaroxaban (15 mg twice daily for 21 days, followed by

19 ified 1734 propensity-matched patients given rivaroxaban (1751 before propensity matching) and 2945 p

20 fold relative to the ED80 value) compared to rivaroxaban 2 and dabigatran etexilate 1a.

21 duction among those treated with twice-daily rivaroxaban 2.5 mg (HR: 0.56; 95% CI: 0.35 to 0.89; p =

22 In terms of the individual doses, rivaroxaban 2.5 mg reduced cardiovascular death (ITT: 2.

23 m of 180 days of double-blind treatment with rivaroxaban 2.5 mg twice daily or aspirin 100 mg daily.

24 We aimed to assess rivaroxaban 2.5 mg twice daily versus aspirin 100 mg dai

25 s a P2Y12 inhibitor for 12 months (group 1); rivaroxaban 2.5 mg twice daily with stratification to a

26 with DAPT, the administration of twice-daily rivaroxaban 2.5 mg was associated with a reduction in st

27 they underwent randomization to twice daily rivaroxaban 2.5 mg, rivaroxaban 5 mg, or placebo.

28 ts were randomly assigned (1:1:1) to receive rivaroxaban (2.5 mg orally twice a day) plus aspirin (10

29 re randomly assigned (1:1:1) to receive oral rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg on

30 bitor for 12 months (group 1), very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or

31 t international normalized ratio=2.0-3.0) or rivaroxaban (20 mg daily; 15 mg if creatinine clearance

32 r bleeding were compared across the 3 drugs (rivaroxaban: 20 mg QD, dabigatran: 150 mg BID, or warfar

33 Rivaroxaban 5 mg twice a day compared with aspirin alone

34 ng occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin

35 omization to twice daily rivaroxaban 2.5 mg, rivaroxaban 5 mg, or placebo.

36 men, 55.8%; NOAC dabigatran, 45347 patients; rivaroxaban, 54006 patients; and apixaban, 12886 patient

37 ts during/within 3 days after last intake of rivaroxaban (58.9% minor, 35.0% of nonmajor clinically r

38 A and 8,734 (44.6%) were treated with NOACs (rivaroxaban 7,572, apixaban 1,066, and dabigatran 96).

39 tions had lower rates of major bleeding with rivaroxaban (adjusted hazard ratio, 0.71; 95% confidence

40 we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as comp

41 uate the safety of continuous periprocedural rivaroxaban administration during left atrial radiofrequ

42 ice a day) plus aspirin (100 mg once a day), rivaroxaban alone (5 mg orally twice a day), or aspirin

43 By comparison, treatment with rivaroxaban alone did not significantly improve the prim

44 Rivaroxaban alone did not significantly reduce major adv

45 and similarly, more bleeds were seen in the rivaroxaban alone group than in the aspirin alone group

46 us aspirin, in 84 [1%] patients who received rivaroxaban alone, and in 61 [1%] patients who received

47 Rivaroxaban, an oral factor Xa inhibitor, might simplify

48 o GI bleeding were <90 days for apixaban and rivaroxaban and <120 days for dabigatran.

49 rred in 16 (5%) of 354 patients allocated to rivaroxaban and 20 (7%) of 301 patients allocated to eno

50 e 5, 2013, and Nov 11, 2014, 54 who received rivaroxaban and 56 who received warfarin were assessed.

51 < 0001) and an increase in the initiation of rivaroxaban and apixaban (p-value for increasing trend,

52 In conclusion the initiation of rivaroxaban and apixaban is increasing significantly ove

53 d with the least effective strategy and that rivaroxaban and apixaban may be associated with the lowe

54 y of the upstream inhibitors of coagulation (rivaroxaban and apixaban) than dabigatran which is a dir

55 For rivaroxaban and apixaban, anti-Xa activity is linear (R(

56 o 94) from baseline among patients receiving rivaroxaban and by 93% (95% CI, 87 to 94) among patients

57 Rivaroxaban and dabigatran are already licensed for VTE

58 tamin K antagonist oral anticoagulant agents rivaroxaban and dabigatran are superior to warfarin for

59 Compared with warfarin, both rivaroxaban and dabigatran significantly decreased the r

60 nts, bleeding, and mortality associated with rivaroxaban and dabigatran versus warfarin in Asians wit

61 -world practice among Asians with NVAF, both rivaroxaban and dabigatran were associated with reduced

62 effectiveness of direct oral anticoagulants (rivaroxaban and dabigatran), compared to each other and

63 margin of 4.5% (absolute difference between rivaroxaban and fondaparinux).

64 7 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving

65 rred in eight (2%) of 353 patients receiving rivaroxaban and in 15 (5%) of 298 patients receiving sta

66 curred in 48 (14%) of 353 patients receiving rivaroxaban and in 49 (16%) of 298 patients receiving st

67 -factor Xa activity among patients receiving rivaroxaban and of 30% among those receiving apixaban.

68 We describe a correlation between rivaroxaban and spontaneous vitreous hemorrhage.

69 differed among participants with WRF taking rivaroxaban and those taking warfarin.

70 al, 0.47-1.85) risks were comparable between rivaroxaban and VKA new users.

71 stics and compared adjusted outcomes between rivaroxaban and warfarin according to number of concomit

72 principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/10

73 1 [0.3%], respectively; p = 1.0) between the rivaroxaban and warfarin groups in the first 30 days.

74 Rivaroxaban and warfarin had similar risk for major/nonm

75 domized, double-blind, double-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillat

76 patients who redeemed prescriptions for both rivaroxaban and warfarin, or other oral anticoagulants.

77 nt bleeding (principal safety endpoint) with rivaroxaban and warfarin.

78 oxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of

79 bigatran etexilate mesylate, 2 administering rivaroxaban, and 3 administering apixaban) enrolling a t

80 d 17 eligible studies for dabigatran, 15 for rivaroxaban, and 4 for apixaban.

81 ationship between drug levels of dabigatran, rivaroxaban, and apixaban and coagulation assay results.

82 Dabigatran, rivaroxaban, and apixaban exhibit variable effects on co

83 of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban.

84 mized trials of DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban) for efficacy and bleeding out

85 anticoagulant agents (apixaban, dabigatran, rivaroxaban, and warfarin) for their effects on 4 renal

86 Among dabigatran-, rivaroxaban-, and their VKA-matched-treated patients, 55

87 Rivaroxaban anticoagulation may be associated with spont

88 taneous vitreous hemorrhage after initiating rivaroxaban anticoagulation.

89 New oral anticoagulants (such as dabigatran, rivaroxaban, apixaban and edoxaban) offer relative effic

90 inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are effective and safe alternativ

91 of patients with VTE were initiated on VKA, rivaroxaban, apixaban, and dabigatran.

92 to reverse the effects of the anti-Xa NOACs (rivaroxaban, apixaban, and edoxaban), and a number of ot

93 n of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban), many have question

94 oagulants (NOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to repla

95 anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, and edoxaban, provide potential a

96 erature review of HIT treatment using DOACs (rivaroxaban, apixaban, dabigatran, edoxaban).

97 In Phase III trials, rivaroxaban, apixaban, edoxaban (antifactor Xa agents),

98 rectly target factor IIa (dabigatran) or Xa (rivaroxaban, apixaban, edoxaban) are available.

99 3 trials that compared dabigatran etexilate, rivaroxaban, apixaban, or edoxaban with VKA therapy in p

100 ared a novel oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) with warfarin, and r

101 ption of OAC overall, direct OAC (dabigatran/rivaroxaban/apixaban), and multivariable associations be

102 (NOACs) apixaban, dabigatran, edoxaban, and rivaroxaban are administered in fixed doses without anti

103 Dabigatran and rivaroxaban are new oral anticoagulants that are elimina

104 p 3], and group 3=29.3%) were reduced in the rivaroxaban arms compared with the VKA arm, but other fo

105 warfarin did not differ with age, supporting rivaroxaban as an alternative for the elderly.

106 These findings support the use of rivaroxaban as an alternative to warfarin in patients wi

107 3 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%)

108 ose NOACs (dabigatran at 150 mg twice daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg tw

109 ose NOACs (dabigatran at 150 mg twice daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg tw

110 recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prop

111 thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of as

112 oronary syndromes event to either aspirin or rivaroxaban based on a computer-generated randomisation

113 ial fibrillation who initiated dabigatran or rivaroxaban between July and November 2012 or VKA betwee

114 ified who initiated apixaban, dabigatran, or rivaroxaban between October 1, 2010, and September 30, 2

115 within 7 days of study drug initiation with rivaroxaban, but after 30 days, rivaroxaban was associat

116 Rivaroxaban carried a significantly higher risk for hosp

117 nd safety of a single-drug regimen with oral rivaroxaban compared with enoxaparin followed by vitamin

118 investigated the safety and effectiveness of rivaroxaban compared with standard anticoagulation thera

119 The efficacy of rivaroxaban compared with warfarin was similar in patien

120 d risk of ischemic stroke in patients taking rivaroxaban, compared with dabigatran and warfarin, seem

121 ebo (14 participants) (P<0.001), and unbound rivaroxaban concentration was reduced by 23.4 ng per mil

122 Therefore, rivaroxaban could offer patients with symptomatic superf

123 rse drug events; 4 anticoagulants (warfarin, rivaroxaban, dabigatran, and enoxaparin) and 5 diabetes

124 Novel oral anticoagulants (NOACs) (rivaroxaban, dabigatran, apixaban) have been approved by

125 Patients treated with one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA were identifie

126 continue with warfarin or receive 20 mg oral rivaroxaban daily.

127 ven 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily.

128 Rivaroxaban deactivated HSC, with decreased alpha-smooth

129 ETP for rivaroxaban did not reach the non-inferiority threshold,

130 owed by the full dose of 220 mg once daily), rivaroxaban (dose of 10 mg once daily, with the first do

131 95% CI, 0.4%-11.3%) in patients treated with rivaroxaban during acute HIT (group A, n = 25; group B,

132 patients are being started on dabigatran and rivaroxaban, even when their use is contraindicated and

133 for 13,084 patients, and data on apixaban vs rivaroxaban for 13,130 patients.

134 (when we completed our prospective study of rivaroxaban for HIT), using rivaroxaban for serologicall

135 XA inhibition with rivaroxaban for Long-term and Initial Anticoagulation in

136 ul to clinicians considering a transition to rivaroxaban for patients receiving VKA therapy.

137 pective study of rivaroxaban for HIT), using rivaroxaban for serologically confirmed HIT (4Ts score >

138 Following approval of rivaroxaban for the pulmonary embolism indication, patie

139 The efficacy and safety of the anticoagulant rivaroxaban for the treatment and secondary prevention o

140 Peak thrombin generation was lower in the rivaroxaban group (56 nmol/L, 95% CI 47-66 vs 86 nmol/L,

141 study and 472 were randomly assigned to the rivaroxaban group (n=236) or the fondaparinux group (n=2

142 of major bleeding was 0.8% (19/2505) in the rivaroxaban group and 2.1% (43/2010) in the standard ant

143 us thromboembolism was 1.4% (36/2505) in the rivaroxaban group and 2.3% (47/2010) in the standard ant

144 of interest) comprised 2619 patients in the rivaroxaban group and 2149 in the standard anticoagulant

145 ortality frequency was 0.4% (11/2505) in the rivaroxaban group and 3.4% (69/2010) in the standard ant

146 (3%) of 211 patients (95% CI 1.6-6.7) in the rivaroxaban group and in four (2%) of 224 patients (0.7-

147 n the two groups (944 [36.0%] of 2619 in the rivaroxaban group vs 805 [37.5%] of 2149 in the standard

148 of cancer (five [2%] of 233 patients in the rivaroxaban group vs five [2%] of 236 in the standard th

149 history of cancer (one [<1%] patient in the rivaroxaban group vs four [2%] patients in the standard

150 Patients in the rivaroxaban group were younger and fewer had active canc

151 group was not seen in the extended-duration rivaroxaban group.

152 There was one death in the rivaroxaban group; this patient died from cardiogenic sh

153 WRF patients who were randomized to receive rivaroxaban had a reduction in stroke or systemic emboli

154 th active cancer and venous thromboembolism, rivaroxaban had similar efficacy to prevent recurrence o

155 n (HR, 0.39; 95% CI, 0.27-0.58; P < .001) or rivaroxaban (HR, 0.33; 95% CI, 0.22-0.49; P < .001).

156 dabigatran (HR, 0.45; 95% CI, 0.29-0.71) or rivaroxaban (HR, 0.39; 95% CI, 0.25-0.61).

157 Rivaroxaban (HR, 0.55; 95% CrI, 0.35-0.89) and apixaban

158 d the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes

159 We explore the safety and efficacy of rivaroxaban in patients with heart failure (HF).

160 tion in hemorrhagic stroke was observed with rivaroxaban in patients with HF as in the overall trial

161 RETATION: In this clinical practice setting, rivaroxaban in patients with unprovoked VTE was associat

162 Data about the use of rivaroxaban in the setting of left atrial RFA procedures

163 rombotic therapy approach combining low-dose rivaroxaban (in place of aspirin) with a P2Y12 inhibitor

164 In the ROCKET AF trial, rivaroxaban increased GI bleeding compared with warfarin

165 t published data for apixaban, edoxaban, and rivaroxaban indicate that further work is needed to clar

166 Rivaroxaban is a factor Xa inhibitor that was recently r

167 opensity score-adjusted results confirm that rivaroxaban is a safe and effective alternative to stand

168 Rivaroxaban is an anticoagulant prescribed for the manag

169 Rivaroxaban is established for the treatment and seconda

170 Rivaroxaban is increasingly prescribed as a replacement

171 Worldwide, rivaroxaban is increasingly used for stroke prevention i

172 ivaroxaban or fondaparinux to assess whether rivaroxaban is non-inferior to fondaparinux in the preve

173 erotonin release) with successful outpatient rivaroxaban management of HIT-associated thrombosis.

174 NOACs, particularly dabigatran and rivaroxaban, may be associated with lower risks of adver

175 t the end of the study had more strokes with rivaroxaban (n = 22) versus warfarin (n = 6, 6.42 vs. 1.

176 ted of consecutive patients with NVAF taking rivaroxaban (n = 3,916), dabigatran (n = 5,921), or warf

177 eased risk of abnormal uterine bleeding with rivaroxaban needs further exploration.

178 Dabigatran and rivaroxaban new users were matched to VKA new users by t

179 sed of 19 713 VKA, 8443 dabigatran, and 4651 rivaroxaban new users.

180 450 3A4 and P-glycoprotein inhibitors in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition

181 e and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition

182 varoxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibitio

183 In the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibitio

184 ug in the on-treatment arm of the ROCKET AF (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition

185 dditional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition

186 eeding) end points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibitio

187 ssigned patients (1:1) to receive 10 mg oral rivaroxaban or 2.5 mg subcutaneous fondaparinux once a d

188 4 patients received PCCs for the reversal of rivaroxaban or apixaban due to a MBE.

189 s for the management of MBEs associated with rivaroxaban or apixaban is effective in most cases and i

190 investigate temporal trends in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K a

191 2016, we prospectively included patients on rivaroxaban or apixaban treated with PCCs for the manage

192 ncreasing age was associated with upstart of rivaroxaban or apixaban with reference to age <65 within

193 en for the management of MBEs in patients on rivaroxaban or apixaban.

194 likely to be initiated on VKA compared with rivaroxaban or apixaban.

195 anagement of major bleeding events (MBEs) on rivaroxaban or apixaban.

196 rombin, mice were fed chow containing either rivaroxaban or dabigatran, respectively.

197 ients (n=12 612) randomly assigned to either rivaroxaban or dose-adjusted warfarin.

198 ears who were receiving anticoagulation with rivaroxaban or enoxaparin/VKA for confirmed VTE.

199 sis and additional risk factors given either rivaroxaban or fondaparinux to assess whether rivaroxaba

200 wice-daily doses of either 2.5 mg or 5 mg of rivaroxaban or placebo for a mean of 13 months and up to

201 patients who did not have a prescription for rivaroxaban or warfarin within 7 days of VTE, and patien

202 osis of unprovoked VTE who were new users of rivaroxaban or warfarin.

203 hat were similar among patients treated with rivaroxaban or warfarin.

204 associated with initiating VKA, dabigatran, rivaroxaban, or apixaban for patients aged >/=85 years w

205 at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through D

206 lation with incident exposure to dabigatran, rivaroxaban, or apixaban from October 1, 2010 through Fe

207 embolism in patients who started dabigatran, rivaroxaban, or warfarin.

208 enal function who were randomized to receive rivaroxaban (P=0.050 for interaction).

209 October 1, 2011, and December 31, 2013, 1776 rivaroxaban patients were enrolled.

210 a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day).

211 tents, the administration of either low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months or very

212 We hypothesized that a regimen of rivaroxaban plus a P2Y12 inhibitor monotherapy or rivaro

213 also a significant net benefit in favour of rivaroxaban plus aspirin and deaths were reduced by 23%.

214 The use of the rivaroxaban plus aspirin combination increased major ble

215 The combination of rivaroxaban plus aspirin compared with aspirin alone red

216 Rivaroxaban plus aspirin reduced mortality when compared

217 The combination of rivaroxaban plus aspirin reduced the primary outcome mor

218 Combined rivaroxaban plus aspirin treatment resulted in more majo

219 g in 130 [2%] patients who received combined rivaroxaban plus aspirin, in 84 [1%] patients who receiv

220 oxaban plus a P2Y12 inhibitor monotherapy or rivaroxaban plus DAPT could reduce bleeding and thereby

221 Y12 inhibitor for 12 months or very-low-dose rivaroxaban plus DAPT for 1, 6, or 12 months was associa

222 ctiveness and safety of anticoagulation with rivaroxaban plus either one or two antiplatelet agents a

223 onfidence interval, 1.21-1.81; P=0.0001) and rivaroxaban (rate ratio, 1.38; 95% confidence interval,

224 confidence interval, 1.18-2.68; P=0.006) and rivaroxaban (rate ratio, 1.71; 95% confidence interval,

225 The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when

226 s thromboembolism, but little is known about rivaroxaban-related bleeding complications in daily care

227 e analyzed rates, management, and outcome of rivaroxaban-related bleeding.

228 r data indicate that, in real life, rates of rivaroxaban-related major bleeding may be lower and that

229 ger patients, but the efficacy and safety of rivaroxaban relative to warfarin did not differ with age

230 ps; there was no interaction between age and rivaroxaban response.

231 gates the effects of the oral anticoagulant, rivaroxaban (RVXB), a direct antifactor Xa, on HSC pheno

232 -0.98), and 30 mg (0.46, 0.38-0.57), whereas rivaroxaban showed similar risks.

233 l bleeding events, including 50 who received rivaroxaban, six who received apixaban, and one who rece

234 INTERPRETATION: Low-dose rivaroxaban taken twice a day plus aspirin once a day re

235 g occurred more frequently in patients given rivaroxaban than dabigatran (hazard ratio [HR], 1.20; 95

236 eding were lower in the two groups receiving rivaroxaban than in the group receiving standard therapy

237 At day 42, ETP was higher in the rivaroxaban than in the warfarin group (geometric mean 1

238 erine bleeding occurred more frequently with rivaroxaban than with enoxaparin/VKA (HR, 2.13; 95% CI,

239 had the most favorable GI safety profile and rivaroxaban the least favorable profile.

240 are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants s

241 Uninterrupted rivaroxaban therapy appears to be as safe and efficaciou

242 The safety and efficacy of uninterrupted rivaroxaban therapy as a periprocedural anticoagulant fo

243 the feasibility and safety of uninterrupted rivaroxaban therapy during atrial fibrillation (AF) abla

244 prescribed to 88.9%, dabigatran to 9.6%, and rivaroxaban to 1.5%.

245 Thus, addition of rivaroxaban to aspirin has the potential to substantiall

246 stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, bu

247 If transition from rivaroxaban to vitamin K antagonist is needed, timely mo

248 reatment effect was measured as the ratio of rivaroxaban to warfarin for thrombin generation.

249 death (1.88% vs. 3.73%) were similar in the rivaroxaban-treated and warfarin-treated groups.

250 es during the at-risk period were similar in rivaroxaban-treated and warfarin-treated participants (0

251 uring the at-risk period was also similar in rivaroxaban-treated and warfarin-treated participants (0

252 Among the rivaroxaban-treated participants, anti-factor Xa activit

253 recurrent venous thromboembolism were low in rivaroxaban-treated patients and consistent with phase 3

254 stroke and non-CNS embolism was observed in rivaroxaban-treated patients compared with warfarin-trea

255 In routine clinical practice, rivaroxaban-treated patients had a lower risk profile at

256 All dabigatran- and rivaroxaban-treated patients were matched to 16 014 and

257 significant relationships in dabigatran- or rivaroxaban-treated patients without a renal indication.

258 ice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once

259 y plus P2Y12 inhibitor monotherapy or 2.5 mg rivaroxaban twice daily plus DAPT was associated with a

260 point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with a

261 In men, rivaroxaban use decreased stroke risk when compared with

262 However, data about rivaroxaban use in routine clinical practice are needed.

263 Since then, dabigatran and rivaroxaban use in the atrial fibrillation-end-stage ren

264 g left atrial RFA, continuous periprocedural rivaroxaban use seems to be as safe as uninterrupted per

265 k was similar in the 3 anticoagulant groups, rivaroxaban use significantly increased the risk for any

266 was 2.4 per 100 person-years at 6 months in rivaroxaban users versus 2.0 in warfarin users (HR 1.19,

267 was 9.9 incidents per 100 person-years with rivaroxaban versus 13.1 incidents per 100 person-years w

268 ism rates were consistent among older (2.29% rivaroxaban versus 2.85% warfarin per 100 patient-years;

269 equally in both groups (20 of 272; 7% in the rivaroxaban versus 33 of 272, 12% in the phenprocoumon;

270 ere major bleeding rates (>/=75 years: 4.86% rivaroxaban versus 4.40% warfarin per 100 patient-years;

271 ically significant bleeding was similar with rivaroxaban versus aspirin therapy (total 154 patients [

272 ession to compare rates of the outcomes with rivaroxaban versus standard treatment.

273 We compare effectiveness and safety of rivaroxaban versus warfarin in a prospective cohort of r

274 safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors a

275 rapeutic international normalized ratio with rivaroxaban versus warfarin.

276 of major or nonmajor clinical GI bleeding in rivaroxaban- versus warfarin-treated patients (3.61 even

277 We compared data on rivaroxaban vs dabigatran for 31,574 patients, data on a

278 t significantly different for treatment with rivaroxaban vs warfarin (HR, 0.84; 95% CI, 0.49-1.44).

279 CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0

280 receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [

281 was 0.31 (95% CI, 0.01-7.69), and the OR for rivaroxaban was 1.48 (95% CI, 1.21-1.82).

282 tiation with rivaroxaban, but after 30 days, rivaroxaban was associated with less bleeding in VKA-nai

283 After 30 days, rivaroxaban was associated with less bleeding than warfa

284 Among patients with on-treatment WRF, rivaroxaban was associated with lower rates of stroke an

285 wer risks of >/=30% decline in eGFR and AKI; rivaroxaban was associated with lower risks of >/=30% de

286 AN with enoxaparin) trial, extended-duration rivaroxaban was compared with standard-duration enoxapar

287 INTERPRETATION: Rivaroxaban was non-inferior to fondaparinux for treatme

288 In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-d

289 The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxab

290 ermine whether prescription of dabigatran or rivaroxaban was occurring in the dialysis population and

291 r nonmajor clinically relevant bleeding with rivaroxaban was similar to warfarin in patients with HF

292 Rivaroxaban was tolerated across complex patients on mul

293 Patients taking uninterrupted periprocedural rivaroxaban were matched by age, sex, and type of AF wit

294 aroxaban 15 or 20 mg/d before the procedure (rivaroxaban) were matched by age, sex, and type of rhyth

295 ist (VKA) oral anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-nai

296 rombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of

297 ospitalized medically iLL patients comparing rivaroxabAN with enoxaparin) trial, extended-duration ri

298 these results, a head-to-head comparison of rivaroxaban with long-term low-molecular-weight heparin

299 the ROCKET AF (Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke a

300 (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke a